Orange Book product · Generic (ANDA)
ABACAVIR SULFATE AND LAMIVUDINE
ABACAVIR SULFATE; LAMIVUDINE
At a glance
Sep 29, 2016
Approved
Generic (ANDA)
Application
Not listed
TE code
None
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Sep 29, 2016
9 yr 10 mo ago
Today
Pharmaceutical detail
Active ingredient
ABACAVIR SULFATE; LAMIVUDINE
Strength
EQ 600MG BASE;300MG
Dosage form
TABLET
Route
ORAL
TE code
Not listed
Application
ANDA 079246
Product number
001
Marketing status
DISCN
Reference listed drug (RLD)
No
Reference standard (RS)
No
Active-ingredient family
View full familyGeneric (ANDA) of ABACAVIR SULFATE; LAMIVUDINE
- 2023ABACAVIR SULFATE AND LAMIVUDINEBrand (NDA)
NDA 204311 · PHARMOBEDIENT
- 2004EPZICOMBrand (NDA)
NDA 021652 · VIIV HLTHCARE
- 2025ABACAVIR SULFATE AND LAMIVUDINEGeneric (ANDA)
ANDA 205412 · HETERO LABS LTD V
- 2024ABACAVIR SULFATE AND LAMIVUDINEGeneric (ANDA)
ANDA 212663 · MACLEODS PHARMS LTD
- 2022ABACAVIR SULFATE AND LAMIVUDINEGeneric (ANDA)
ANDA 216332 · LAURUS
- 2018ABACAVIR SULFATE AND LAMIVUDINEGeneric (ANDA)
ANDA 090159 · AUROBINDO PHARMA LTD
- 2018ABACAVIR SULFATE AND LAMIVUDINEGeneric (ANDA)
ANDA 208990 · ZYDUS PHARMS
- 2017ABACAVIR SULFATE AND LAMIVUDINEGeneric (ANDA)
ANDA 206151 · AUROBINDO PHARMA
- 2017ABACAVIR SULFATE AND LAMIVUDINEGeneric (ANDA)
ANDA 204990 · CHARTWELL RX
- 2017ABACAVIR SULFATE AND LAMIVUDINEGeneric (ANDA)
ANDA 091144 · CIPLA
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
